

Index

- AAA. *See* abdominal aortic aneurysm
 AABB, clinical guidelines for RBC transfusion thresholds, 139
 AAMI. *See* Association for the Advancement of Medical Instrumentation
 AARKS. *See* automated anesthesia record keepers
 abdominal aortic aneurysm (AAA), 96
 abdominal ultrasound, 92, 98
 aortic, 96
 FAST exam, 92–93
 key points, 97
 left upper quadrant (perisplenic) view, 93–94
 limitations of, 95–96
 pelvic view, 94
 right upper quadrant (perihepatic) view, 93
 subcostal view, 94–95
 gallbladder, 97
 pneumoperitoneum detection on, 97
 transducer selection, 92
 ACLS. *See* advanced cardiac life support
 acoustic respiratory rate (RRa[®]) monitoring, 152
 activated clotting time (ACT), 123
 acute respiratory distress syndrome (ARDS)
 EVLW measurement in, 119
 TTE of, 63
 ultrasound, 72
 advanced cardiac life support (ACLS), NIRS monitoring in, 26
 AI. *See* aortic insufficiency
 AIMS. *See* Anesthesia Information Management Systems
 alarm fatigue, 173, 175–178
 American Society of Anesthesiologists (ASA), 173
 Standards for Basic Anesthetic Monitoring, 139
 American Society of
 Echocardiography, basic TEE views, 36, 37
 descending aortic
 long-axis view, 39
 descending aortic short-axis view, 39
 mid-esophageal aortic valve short-axis view, 38
 mid-esophageal ascending aortic long-axis view, 38
 mid-esophageal ascending aortic short-axis view, 38
 mid-esophageal bi-caval view, 38
 mid-esophageal four-chamber view, 37–38
 mid-esophageal long-axis view, 38
 mid-esophageal right ventricular inflow-outflow view, 38
 mid-esophageal two-chamber view, 38
 transgastric mid-papillary short-axis view, 36
 analytics, technology convergence with, 169–170
 Anesthesia Information Management Systems (AIMS)
 digital distraction due to, 173
 performance improvement using, 159
 decision support systems, 155, 156–159
 electronic anesthesia records, 154–155
 history of, 154
 anesthesiology
 digital distraction in, 173–174, 178
 alarm fatigue, 173, 175–178
 culture change to address, 175
 distracted doctoring, 174–175
 recent evolution in, 173
 vigilance in, 173
 antibiotic administration, DSS for, 156
 anticoagulation monitoring, 123
 aorta, ultrasound evaluation, 96
 aortic disease, TEE of, 51–52
 aortic dissection, 96
 aortic insufficiency (AI), 44, 45, 46
 aortic valve, TEE evaluation, 41–42
 aortic regurgitation, 44, 45, 46
 aortic stenosis, 42–43
 aortic valve velocity time integral (VTI_{AV}), 86–88
 apical four- and five-chamber views, TTE, 56, 58–61, 62
 apixaban, 124, 125
 apnea, ultrasound, 72
 ARDS. *See* acute respiratory distress syndrome
 arterial waveform analysis, 101–102, 104
 calibrated devices, 102
 fluid responsiveness monitors, 112, 115
 lithium dilution, 102
 transpulmonary thermodilution, 102
 uncalibrated devices, 102
 empiric approach, 102
 fluid responsiveness monitors, 112, 115
 Pressure Recording Analytical Method, 102
 artifacts, lung ultrasound, 68–69, 70
 atelectasis, 72, 74
 consolidation, 72, 74
 increased water, 71–73
 normal, 69–70
 pleural effusions, 72, 73
 pneumothorax, 70–71, 72, 73
 ASA. *See* American Society of Anesthesiologists
 assay method, blood loss assessment, 140, 145
 Association for the Advancement of Medical Instrumentation (AAMI), Alarm Standards Committee, 176
 asthma, ultrasound, 72
 atelectasis, ultrasound, 72, 74
 automated anesthesia record keepers (AARKS), 154–155
 autoregulation. *See* cerebral autoregulation
 BAT. *See* blunt abdominal trauma
 Bernoulli principle, 41
 bias, 2–4
 “big data,” 15–16
 billing, DSS for, 159
 bioimpedance
 cardiac output measurement, 103, 104
 respiratory volume monitoring, 151–152

- bioreactance
 cardiac output measurement, 103, 104
 fluid responsiveness, 112, 115
 blackberry thumb, 174
 Bland–Altman analysis, 2–4, 6–8
 blood flow. *See* cerebral blood flow
 blood loss. *See* intraoperative blood loss
 blood pressure
 DSS for, 156
 variation with positive pressure ventilation, 110–111
 variation with respiration, 110
 wireless monitoring, 166
 blunt abdominal trauma (BAT), FAST exam, 92, 93
 brain metabolism monitoring, 14–15
 brain oxygen monitoring, 13. *See also* cerebral oximetry
 invasive, 13–14
 noninvasive, 14
 brain physiology, 10–11

 capnography, 150–151
 cardiac arrest, 64
 cardiac output (CO), fluid responsiveness, 81
 cardiac output (CO) monitoring. *See also* noninvasive cardiac output monitoring
 validation studies
 background, 2–3
 Bland–Altman analysis, 2–4, 6–8
 measurement of output, 1–2
 protocol design and data collection, 2
 report of validation study data, 6–8
 time plots and regression analysis, 5–6
 trend analysis, 2–3, 4–5
 cardiac tamponade, 51, 63
 cardiac telemetry, 165–166
 Cardio Q, 112–113, 115
 cardiogenic shock, 63
 CardioMEMSTM heart failure sensor, 166
 cardiopulmonary bypass (CPB), 24
 cardiopulmonary resuscitation
 NIRS monitoring in, 26
 TTE in, 64
 carotid endarterectomy (CEA), 24
 carotid velocity time integrals, 88
 heart–lung interaction model, 88
 image acquisition, 88, 89
 passive leg raise test, 88–89
 CBF. *See* cerebral blood flow
 CCA. *See* common carotid artery

 CCV_{max}. *See* common carotid maximal velocity
 CEA. *See* carotid endarterectomy
 cEEG. *See* continuous electroencephalography
 central venous pressure (CVP), fluid administration in shock, 80–81
 cerebral autoregulation, 10–11
 monitoring of, 14
 NIRS monitoring index for, 25
 cerebral blood flow (CBF), 10–11, 12
 invasive monitoring, 12
 noninvasive monitoring, 12–13
 cerebral microdialysis (MD), 14–15
 cerebral oximetry, 14, 20, 26
 in clinical practice, 24
 cardiopulmonary bypass, 24
 cardiopulmonary resuscitation, 26
 carotid endarterectomy, 24
 cerebral autoregulation index, 25
 general surgery, 25
 orthopedic surgery, 24–25
 postoperative cognitive decline, 25–26
 traumatic brain injury, 26
 interpretation, 22–23
 NIRS principles, 20–21, 22
 cerebral oximetry index (COx), 25
 cerebral perfusion pressure (CPP), 10–11, 14
 chart review, DSS for, 156
 chronic obstructive pulmonary disease (COPD), 72
 ClearSight System, 112, 115
 clinical alarms, 176. *See also* alarm fatigue
 clinical examination, neurological injuries, 10
 CNAPTM, 112, 115
 CO. *See* cardiac output
 coagulation tests. *See* hematology
 Cochrane reviews, 1
 common bile duct, 97
 common carotid artery (CCA), 88–89
 common carotid maximal velocity (CCV_{max}), 88
 compensation, DSS for, 159
 compliance, DSS for, 159
 computer stations, digital distraction due to, 173–175
 concordance analysis, 4, 5
 cone and plate(let) analyzer (CPA), 125
 consolidation, pulmonary, 72, 74
 consumer wearables, 167
 e-textiles, 168
 ocular devices, 168–169
 smartwatches, 168
 contact lens monitoring, 168–169
 continuous electroencephalography (cEEG), 15
 contractility, 81
 COPD. *See* chronic obstructive pulmonary disease
 cor pulmonale, 63, 64
 coronary ischemia, 41, 42
 corrective actions, DSS for, 156
 cost containment, DSS for, 158–159
 COx. *See* cerebral oximetry index
 CPA. *See* cone and plate(let) analyzer
 CPB. *See* cardiopulmonary bypass
 CPP. *See* cerebral perfusion pressure
 crisis avoidance, DSS for, 156–157
 culture of patient safety, 175
 CVP. *See* central venous pressure
 cyanosis, 148

 dabigatran, 124–125
 data collection, 2
 decision support systems (DSS), 155
 antibiotic administration, 156
 billing, 159
 blood pressure, 156
 chart review, 156
 compensation, 159
 compliance, 159
 corrective actions, 156
 cost containment, 158–159
 crisis avoidance, 156–157
 drug diversion, 157–158
 packages, 157
 postoperative nausea and vomiting prophylaxis, 156
 relief equity, 158
 resident monitoring, 158
 risk reduction, 157
 dependency, PED, 174
 descending aortic long-axis view, TEE, 39
 descending aortic short-axis view, TEE, 39
 desensitization, to alarm stimuli, 173, 175–178
 diabetes mellitus, 169–170
 digital distraction, 173–174, 178
 alarm fatigue, 173, 175–178
 culture change to address, 175
 distracted doctoring, 174–175
 dilute thrombin time assay, 124
 direct oral anticoagulants (DOACs), 124–125
 direct thrombin inhibitors (DTI), 124–125
 distracted doctoring, 174–175
 distraction. *See* digital distraction
 distributive shock, 63
 DOACs. *See* direct oral anticoagulants
 drug diversion, DSS for, 157–158
 DSS. *See* decision support systems
 DTI. *See* direct thrombin inhibitors

Index

- dynamic fluid responsiveness
 monitors, 109, 111–112, 115
 applications of
 goal-directed therapy, 113–114
 intraoperative fluid management, 113
 arterial line with calibration, 112, 115
 arterial line without calibration, 112, 115
 noninvasive, 112–113, 115
 physiological basis of, 110
 blood pressure and stroke volume variation, 110–111
 fluid responsiveness assessment using SPV, PPV, SVV, and PVi, 111
 pitfalls and limitations of, 114–115
- Early Goal-Directed Therapy (EGDT) trial, 80–81
- EBL. *See* estimated blood loss
- ecarin clotting time (ECT), 124
- ECG. *See* electrocardiography
- echocardiography. *See* transesophageal echocardiography;
 echocardiography;
 transthoracic
 echocardiography
- ECT. *See* ecarin clotting time
- edoxaban, 124
- EEG. *See* electroencephalography
- EGDT trial. *See* Early Goal-Directed Therapy trial
- electrical velocimetry, cardiac output measurement, 103
- electrocardiography (ECG), wireless, 165–166
- electroencephalography (EEG), 15
- electronic anesthesia records, 154–155.
 See also Anesthesia
 Information Management
 Systems
- electronic distractions. *See* digital distraction
- electronic medical records (EMRs)
 digital distraction due to, 173–175
 performance improvement using, 159
 decision support systems, 155, 156–159
 electronic anesthesia records, 154–155
 history of, 154
 electrophysiology, 15
- EMRs. *See* electronic medical records
- endogenous fluid challenge model, 80, 83–84
- EPs. *See* evoked potentials
- esophageal intubation, ultrasound, 72
- estimated blood loss (EBL), formulas, 141–142, 145, 146
- e-textiles, 168
- EVD. *See* external ventricular drain
- evidence-based approach, to
 monitoring, 1
- EVLW. *See* extravascular lung water
- evoked potentials (EPs), 15
- expired CO₂ monitoring, 150–151
- EXTEM. *See* extrinsic coagulation pathway assay of ROTEM®
- external ventricular drain (EVD), 11
- extravascular lung water (EVLW), 117, 120–121
 measurement of, 118
 in ARDS, 119
 in goal-directed therapy, 120
 in septic shock, 120
 transpulmonary thermodilution, 118–120
 in weaning from mechanical ventilation, 120
 physiology of accumulation of, 117–118
- extrinsic coagulation pathway assay of ROTEM® (EXTEM), 125
- eyeglass sensors, 168–169
- FAC. *See* fractional area change
- factor Xa inhibitors, 124, 125
- false alarms, 176
- FAST. *See* focused assessment with sonography in trauma
- Fick, Adolf Eugen, 100
- Fick method, cardiac output measurement with, 1, 100
- Fitbit, 168
- FloTrac, 102, 112, 115
- fluid
 abdominal, FAST exam, 92–94, 95–96
 lung
 EVLW, 117–121
 ultrasound of, 71–73
- fluid administration
 dynamic fluid responsiveness monitors, 113–114
 for shock, 80–81, 109
- fluid responsiveness
 definition of, 81
 dynamic monitors, 109, 111–112, 115
 arterial line with calibration, 112, 115
 arterial line without calibration, 112, 115
 goal-directed therapy with, 113–114
 intraoperative fluid management with, 113
- noninvasive, 112–113, 115
 physiological basis of, 110–111
 pitfalls and limitations of, 114–115
- heart–lung interaction model, 80, 81–83
- passive leg raise test, 80, 83–84
- in shock and hypotension, 80–81, 109
- ultrasound techniques, 84, 89
 carotid velocity time integrals, 88–89
 FAST exam, 95
 inferior vena cava diameter evaluation, 84–86
 left ventricular outflow tract/aortic valve velocity time integral evaluation, 86–88
- focused assessment with sonography in trauma (FAST), 92–93
 key points, 97
 left upper quadrant (perisplenic) view, 93–94
 limitations of, 95–96
 pelvic view, 94
 right upper quadrant (perihepatic) view, 93
 subcostal view, 94–95
- FOMO, 174
- formulas, blood loss calculations, 141–142, 145, 146
- four-quadrant plot, 4, 5
- fractional area change (FAC)
 left ventricular, 39, 40
 right ventricular, 39–40, 41
- Frank Starling Curve (FSC), 81
- future monitoring technologies, 164, 171
 analytics and technology convergence, 169–170
 challenges with, 170–171
 consumer wearables, 167
 e-textiles, 168
 ocular devices, 168–169
 smartwatches, 168
 wireless, 164–165
 blood pressure monitoring, 166
 cardiac telemetry, 165–166
 pulse oximetry, 166–167
- gallbladder, ultrasound, 97
- GEM 4000, 142–143
- general surgery, NIRS monitoring in, 25
- global thrombosis test (GTT), 125, 126
- goal-directed therapy
 dynamic fluid responsiveness monitors, 113–114
 EVLW measurement in, 120

- gravimetric blood loss determination, 140–141, 145
 GTT. *See* global thrombosis test
- Hb. *See* hemoglobin
 Hct. *See* hematocrit
 heart–lung interaction model (HLIM)
 carotid velocity time integrals, 88
 fluid responsiveness, 80, 81–83
 VTI_{LVOT} variation, 87–88
 hematocrit (Hct), blood loss
 calculations, 141–142, 145, 146
 hematocrit (Hct) monitoring, 142, 145
 continuous real time, 143
 device overview, 142
 device performance, 142–143
 transfusion decisions, 143
 hematology point-of-care tests, 123, 133
 anticoagulation monitoring, 123
 direct oral anticoagulant monitoring, 124–125
 direct thrombin inhibitor monitoring, 124–125
 global thrombosis test, 125, 126
 IMPACT-R™, 125
 platelet function tests, 129–130
 Innovance® PFA-100/200, 130–131
 Multiplate®, 131–132
 PlateletWorks®, 132
 TEG® and ROTEM®, 131, 132
 VerifyNow system, 130, 131
 viscoelastic coagulation tests, 125–126
 Quantra Hemostasis Analyzer, 129
 ROTEM®, 126–128, 129
 Sonoclot, 128–129
 TEG®, 126–128, 129
 hemodynamic monitoring. *See* dynamic fluid responsiveness monitors
 hemodynamic resuscitation, 80–81, 109
 hemoglobin (Hb), blood loss
 calculations, 141–142, 145, 146
 hemoglobin (Hb) monitoring, 142, 145
 continuous real time, 143
 device overview, 142
 device performance, 142–143
 transfusion decisions, 143
 hemorrhage. *See* intraoperative blood loss
 hemostasis tests. *See* hematology
 heparin therapy, monitoring, 123
 HLIM. *See* heart–lung interaction model
 hypertension, DSS for, 156
 hypotension
 DSS for, 156
 fluid responsiveness in, 80–81, 109
 hypovolemic shock, 63
- ICP. *See* intracranial pressure
 IMPACT-R™, 125
 inferior vena cava collapsibility index (IVC CI), 85–86
 inferior vena cava (IVC) diameter
 evaluation, 84
 collapsibility index, 85–86
 distensibility index, 85, 86
 image acquisition, 84–85
 inferior vena cava distensibility index (IVC DI), 85, 86
 Innovance® Platelet Function Analyzer (PFA-100/200), 130–131
 intracranial pressure (ICP), 10–11
 intracranial pressure (ICP)
 monitoring, 11
 invasive, 11
 noninvasive, 12
 intraoperative blood loss, 139, 144
 assay method, 140, 145
 formulas, 141–142, 145, 146
 gravimetric method, 140–141, 145
 hemoglobin and hematocrit monitoring, 142, 145
 continuous real time, 143
 device overview, 142
 device performance, 142–143
 transfusion decisions, 143
 imaging analysis, 143–144
 monitoring standard and practice guidelines
 AABB, 139
 ASA, 139
 visual method, 139–140, 145
 intraoperative exam, lung ultrasound
 in, 75–76
 intraoperative fluid management, 113
 intraparenchymal catheters, 13–14
 intravascular volume status, 109, 111–112, 115
 arterial line with calibration, 112, 115
 arterial line without calibration, 112, 115
 goal-directed therapy with, 113–114
 intraoperative fluid management with, 113
 noninvasive, 112–113, 115
 physiological basis of, 110–111
 pitfalls and limitations of, 114–115
 intubation, lung ultrasound, 72, 75
 invasive brain oxygen monitoring, 13–14
 invasive CBF monitoring, 12
 invasive ICP monitoring, 11
 i-STAT, 142–143
- IVC CI. *See* inferior vena cava collapsibility index
 IVC DI. *See* inferior vena cava distensibility index
 IVC diameter evaluation. *See* inferior vena cava diameter evaluation
- Joint Commission, National Patient Safety Goals, 176
 jugular venous oxygen saturation (SvJO₂), 13
- Leaf, 169
 left upper quadrant (LUQ), FAST exam, 93–94
 left ventricle (LV), TEE evaluation, 39, 40
 left ventricular outflow tract velocity
 time integral (VTI_{LVOT}), 86
 heart–lung interaction model, 87–88
 image acquisition, 86–87
 mini-fluid bolus, 88
 passive leg raise test, 88
 LiDCO system, 102, 112, 115
 limits of agreement, 2–3
 lithium dilution
 cardiac output measurement, 102
 fluid analysis, 112, 115
- Livongo, 169
 lung ultrasound, 67, 77
 artifacts, 68–69, 70
 atelectasis, 72, 74
 consolidation, 72, 74
 increased water, 71–73
 normal, 69–70
 pleural effusions, 72, 73
 pneumothorax, 70–71, 72, 73
 in perioperative care
 intraoperative exam, 75–76
 postoperative exam, 76–77
 preoperative exam, 74–75
 sonography for intubation, 72, 75
 technique, 67–68, 69
 lung water, 71–73. *See also* extravascular lung water
 LUQ. *See* left upper quadrant
 LV. *See* left ventricle
- mainstem intubation, ultrasound, 72
 MAP. *See* mean arterial pressure
 Masimo-Radical 7™ pulse oximeter, 113, 115
 McConnell's sign, 95
 MD. *See* cerebral microdialysis
 mean arterial pressure (MAP), 10–11
 mechanical ventilation, EVLW
 measurement in weaning from, 120
 MEPs. *See* motor-evoked potentials

Index

- metabolism, brain, 14–15
 mid-esophageal aortic valve short-axis view, TEE, 38
 mid-esophageal ascending aortic long-axis view, TEE, 38
 mid-esophageal ascending aortic short-axis view, TEE, 38
 mid-esophageal bi-caval view, TEE, 38
 mid-esophageal four-chamber view, TEE, 37–38
 mid-esophageal long-axis view, TEE, 38
 mid-esophageal right ventricular inflow-outflow view, TEE, 38
 mid-esophageal two-chamber view, TEE, 38
 mitral valve, TEE evaluation, 44
 mitral regurgitation, 45–48
 mitral stenosis, 44–45, 46
 monitoring
 digital distraction in, 173–174, 178
 alarm fatigue, 173, 175–178
 culture change to address, 175
 distracted doctoring, 174–175
 evidence-based approach to, 1
 future technologies in, 164, 171
 analytics and technology convergence, 169–170
 challenges with, 170–171
 consumer wearables, 167–169
 wireless monitors, 164–167
 recent evolution in, 173
 vigilance in, 173
 Monroe-Kellie doctrine, 10
 motor-evoked potentials (MEPs), 15
 Moxy Monitor System, 167
 multimodal neurological monitoring, 10
 “big data” in, 15–16
 brain metabolism monitoring, 14–15
 brain oxygen monitoring, 13–14
 brain physiology, 10–11
 CBF monitoring, 12–13
 cerebral autoregulation monitoring, 14
 electrophysiology, 15
 ICP monitoring, 11–12
 Multiple Electrode Aggregometry (Multiplate®), 131–132
 myocardial ischemia
 TEE assessment of, 41, 42
 TTE assessment, 63
 National Institute for Clinical Excellence (NICE), 1
 National Patient Safety Goals, Joint Commission, 176
 near-infrared spectroscopy (NIRS), 14, 20, 26
 in clinical practice, 24
 cardiopulmonary bypass, 24
 cardiopulmonary resuscitation, 26
 carotid endarterectomy, 24
 cerebral autoregulation index, 25
 general surgery, 25
 orthopedic surgery, 24–25
 postoperative cognitive decline, 25–26
 traumatic brain injury, 26
 interpretation, 22–23
 principles, 20–21, 22
 neurological injuries, monitoring paradigm for, 10
 neurological monitoring. *See* multimodal neurological monitoring
 NICE. *See* National Institute for Clinical Excellence
 NICOM™, 112, 115
 NIRS. *See* near-infrared spectroscopy
 nomophobia, 174
 noninvasive brain oxygen monitoring, 14. *See also* cerebral oximetry
 noninvasive cardiac output monitoring, 100, 103–105
 arterial waveform devices, 101–102, 104
 calibrated *versus* uncalibrated, 102
 empiric approach, 102
 lithium dilution, 102
 Pressure Recording Analytical Method, 102
 transpulmonary thermodilution, 102
 bioimpedance and bioreactance, 103, 104
 photoplethysmography, 102–103, 104
 thermodilution, 1–2, 100–101, 104
 ultrasound-based techniques, 101, 104
 noninvasive CBF monitoring, 12–13
 noninvasive dynamic fluid responsiveness monitors, 112–113, 115
 noninvasive ICP monitoring, 12
 nuisance alarms, 176
 obesity, respiratory monitoring and, 148
 obstructive shock, 63, 64
 obstructive sleep apnea (OSA), 148
 ocular devices, consumer wearable, 168–169
 operating room (OR)
 alarms in, 175–178
 distracted doctoring in, 174–175
 evolution of monitoring in, 173
 opioids, respiratory monitoring and, 148
 OR. *See* operating room
 ORi. *See* Oxygen Reserve Index
 orthopedic surgery, NIRS monitoring in, 24–25
 ORx. *See* Oxygen Reactivity Index
 OSA. *See* obstructive sleep apnea
 oximetry. *See* cerebral oximetry
 Oxygen Reactivity Index (ORx), 14
 Oxygen Reserve Index (ORi), 31–34
 oxygen saturation. *See also* regional cerebral oxygen saturation
 jugular venous, 13
 pulse, 30–34
 PAC. *See* pulmonary artery catheter
 parasternal long-axis view, TTE, 55–57, 58
 parasternal short-axis view, TTE, 56, 57–58
 partial pressure of oxygen (PbtO₂), in brain, 13–14
 passive leg raise (PLR)
 carotid velocity time integrals, 88–89
 fluid responsiveness, 80, 83–84
 VTI_{LVO} variation, 88
 PbtO₂. *See* partial pressure of oxygen
 PE. *See* percentage error; pulmonary embolism
 PEDS. *See* personal electronic devices
 pelvic view, FAST, 94
 percentage error (PE), 2–4
 performance improvement, EMRs in, 159
 decision support systems, 155, 156–159
 electronic anesthesia records, 154–155
 history of, 154
 pericardial disease, TEE of, 50
 cardiac tamponade, 51
 pericardial effusion, 50–51
 pericardial effusion
 FAST exam, 94, 95
 TEE of, 50–51
 TTE of, 63
 pericardial tamponade, 94–95
 perihepatic view, FAST, 93
 perioperative care, lung ultrasound in
 intraoperative exam, 75–76
 postoperative exam, 76–77
 preoperative exam, 74–75
 sonography for intubation, 72, 75
 perisplenic view, FAST, 93–94
 personal electronic devices (PEDS), 173–174
 culture change to address, 175
 distracted doctoring and, 174–175

- PFA-100/200. *See* Innovance® Platelet Function Analyzer
- phantom vibration and ringing syndrome, 174
- photometric analysis, blood loss, 140, 145
- photoplethysmography (PPG)
 cardiac output measurement, 102–103, 104
 respiratory monitoring, 151
- phrenic nerve palsy, 72
- physician–patient relationship
 distracted doctoring effects on, 174–175
 recent evolution in, 173
- physiologic alarms, 176
- PiCCO system, 102, 112, 115
- PiCCO 2, 119
- platelet function tests, 129–130
 Innovance® PFA-100/200, 130–131
 Multiplate®, 131–132
 PlateletWorks®, 132
 TEG® and ROTEM®, 131, 132
 VerifyNow system, 130, 131
- platelet monitoring. *See* hematology PlateletWorks®, 132
- pleth variability index (PVi), 109, 111
 fluid responsiveness assessment using, 111
 goal-directed therapy using, 113–114
 monitors displaying, 111–112
 arterial line with calibration, 112, 115
 arterial line without calibration, 112, 115
 noninvasive, 112–113, 115
 pitfalls and limitations of, 114–115
- pleural adhesions, 72
- pleural effusions, 72, 73
- PLR. *See* passive leg raise
- pneumoperitoneum, 97
- pneumothorax, 70–71, 72, 73
- POCD. *See* postoperative cognitive decline
- point-of-care abdominal ultrasound. *See* abdominal ultrasound
- point-of-care hematology. *See* hematology point-of-care tests
- point-of-care lung ultrasound. *See* lung ultrasound
- point-of-care TEE. *See* transesophageal echocardiography
- point-of-care TTE. *See* transthoracic echocardiography
- polar plots, 2–3, 4–5
- PONV prophylaxis. *See* postoperative nausea and vomiting prophylaxis
- positive predictive value (PPV), of alarms, 176, 177
- positive pressure ventilation (PPV)
 blood pressure and stroke volume variation with, 110–111
 heart–lung interaction with, 80, 81–83
- postoperative cognitive decline (POCD), 25–26
- postoperative exam, lung ultrasound in, 76–77
- postoperative nausea and vomiting (PONV) prophylaxis, 156
- PPG. *See* photoplethysmography
- PPV. *See* positive predictive value;
- positive pressure ventilation;
 pulse pressure variation
- PRAM. *See* Pressure Recording Analytical Method
- preload, SV response to, 81
- preload responsiveness. *See* fluid responsiveness
- preoperative exam, lung ultrasound in, 74–75
- pressure and flow assessment, TEE, 41
 aortic valve evaluation, 41–44, 45, 46
 mitral valve evaluation, 44–48
 tricuspid valve evaluation, 48–50
- Pressure Reactivity Index (PRx), 14
- Pressure Recording Analytical Method (PRAM), 102
- Propeller, 169
- protocol design, 2
- PRx. *See* Pressure Reactivity Index
- pulmonary artery catheter (PAC), 1–2, 100–101
- pulmonary bleb, 72
- pulmonary consolidation, 72, 74
- pulmonary embolism (PE), 63, 64, 95
- pulmonary vascular permeability index (PVPI), 119
- pulse contour devices, 101–102, 104
- pulse oximetry, 30–31
 respiratory monitoring, 149–150
 wireless, 166–167
- pulse oxygen saturation (SpO₂)
 monitoring
 Oxygen Reserve Index, 31–34
 pulse oximetry, 30–31
- pulse pressure variation (PPV), 109, 110–111
 fluid responsiveness assessment using, 111
 goal-directed therapy using, 113–114
 monitors displaying, 111–112
 arterial line with calibration, 112, 115
 arterial line without calibration, 112, 115
- noninvasive, 112–113, 115
 pitfalls and limitations of, 114–115
- PVi. *See* pleth variability index
- PVPI. *See* pulmonary vascular permeability index
- Quantra Hemostasis Analyzer, 129
- Radical-7 Pulse CO-Oximeter, 142–143
- radionuclide imaging studies, cardiac output measurement with, 1
- red blood cell (RBC) transfusion, 139
- reference method, cardiac output monitoring, 1–2
- regional cerebral oxygen saturation (rScO₂)
 causes of decreased, 22
 causes of increased, 22
- regional cerebral oxygen saturation (rScO₂) monitoring, 20, 26
 in clinical practice, 24
 cardiopulmonary bypass, 24
 cardiopulmonary resuscitation, 26
 carotid endarterectomy, 24
 cerebral autoregulation index, 25
 general surgery, 25
 orthopedic surgery, 24–25
 postoperative cognitive decline, 25–26
 traumatic brain injury, 26
 interpretation, 22–23
 principles, 20–21, 22
- regional wall motion abnormalities (RWMA)
 TEE assessment, 41, 42
 TTE assessment, 63
- regression analysis, 5–6
- relief equity, DSS for, 158
- report, of validation study data, 6–8
- resident monitoring, DSS for, 158
- respiration, blood pressure variation with, 110
- respiratory failure, 148
- respiratory monitoring, 148–149, 152
 acoustic respiratory rate monitoring, 152
 bioimpedance-based respiratory volume, 151–152
 expired CO₂, 150–151
 photoplethysmography, 151
 pulse oximetry, 149–150
 recent evolution in, 173
 respiratory variation model, 80, 81–83
 respiratory volume monitoring (RVM), 151–152
- Resuscitation Council, 1
- Richtel, Matt, 174
- right upper quadrant (RUQ), FAST exam, 93

Index

- right ventricle (RV)
 TEE evaluation, 39–40, 41
 TTE evaluation, 63–64
 risk reduction, DSS for, 157
 rivaroxaban, 124, 125
 ROTEM®. *See* thromboelastometry
 RRA® monitoring. *See* acoustic
 respiratory rate monitoring
 rScO₂. *See* regional cerebral oxygen
 saturation
 RUQ. *See* right upper quadrant
 RV. *See* right ventricle
 RVM. *See* respiratory volume
 monitoring
 RWMA. *See* regional wall motion
 abnormalities
- SAH. *See* subarachnoid hemorrhage
 sample size, 2
 sensitivity, of alarms, 177
 septic shock, 80–81, 120
 shock
 EVLW measurement in, 120
 fluid responsiveness in, 80–81, 109
 TTE evaluation, 63, 64
 single bolus thermomodulation, 1–2
 smartphones, digital distraction due to,
 173–174
 smartwatches, 168
 somatosensory-evoked potentials
 (SSEPs), 15
 Sonoclot®, 123, 128–129
 SpO₂ monitoring. *See* pulse oxygen
 saturation monitoring
 SPV. *See* systolic pressure variation
 SSEPs. *See* somatosensory-evoked
 potentials
 Standards for Basic Anesthetic
 Monitoring, ASA, 139
 statistics. *See* validation statistics
 Stewart–Hamilton equation, 100–101
 stroke volume (SV), fluid
 responsiveness, 81
 carotid velocity time integrals, 88–89
 heart–lung interaction model, 80,
 81–83
 inferior vena cava diameter
 evaluation, 84–86
 left ventricular outflow tract/aortic
 valve velocity time integral
 evaluation, 86–88
 passive leg raise test, 80, 83–84
 stroke volume variation (SVV), 109
 fluid responsiveness assessment
 using, 111
 goal-directed therapy using,
 113–114
 monitors displaying, 111–112
 arterial line with calibration, 112,
 115
 arterial line without calibration,
 112, 115
 noninvasive, 112–113, 115
 pitfalls and limitations of, 114–115
 with positive pressure ventilation,
 110–111
 study design, 2
 subarachnoid hemorrhage (SAH), 11,
 12–14
 subcostal long- and short-axis views,
 TTE, 56, 60–62
 subcostal view, FAST, 94–95
 SV. *See* stroke volume
 SvjO₂. *See* jugular venous oxygen
 saturation
 SVV. *See* stroke volume variation
 systolic pressure variation (SPV), 109,
 110–111
 fluid responsiveness assessment
 using, 111
 goal-directed therapy using,
 113–114
 monitors displaying, 111–112
 arterial line with calibration, 112,
 115
 arterial line without calibration,
 112, 115
 noninvasive, 112–113, 115
 pitfalls and limitations of, 114–115
- TBI. *See* traumatic brain injury
 tCO₂. *See* transcutaneous CO₂
 monitoring
 TCD. *See* transcranial Doppler
 TDF. *See* thermal diffusion flowmetry
 TEB. *See* thoracic electrical
 bioimpedance
 technical alarms, 176
 technology. *See* digital distraction;
 future monitoring technologies
 TEE. *See* transesophageal
 echocardiography
 TEG. *See* thromboelastogram®
 telemedicine, 170, 173
 thermal diffusion flowmetry (TDF), 12
 thermomodulation. *See also*
 transpulmonary
 thermomodulation
 cardiac output measurement, 1–2,
 100–101, 104
 fluid responsiveness, 112, 115
 thoracic electrical bioimpedance
 (TEB), CO measurement, 103,
 104
 thromboelastogram® (TEG)
 anticoagulation monitoring, 123
 platelet testing, 131, 132
 viscoelastic coagulation testing,
 126–128, 129
 thromboelastometry (ROTEM®)
- platelet testing, 131, 132
 viscoelastic coagulation testing,
 126–128, 129
 time plots, 5–6
 TPTD. *See* transpulmonary
 thermomodulation
 transcranial Doppler (TCD), 12–13
 transcutaneous CO₂ monitoring
 (tcCO₂), 151
 transducer, ultrasound, 92
 transesophageal echocardiography
 (TEE), 35, 52
 American Society of
 Echocardiography basic views,
 36, 37
 descending aortic long-axis view,
 39
 descending aortic short-axis view,
 39
 mid-esophageal aortic valve short-
 axis view, 38
 mid-esophageal ascending aortic
 long-axis view, 38
 mid-esophageal ascending aortic
 short-axis view, 38
 mid-esophageal bi-caval
 view, 38
 mid-esophageal four-chamber
 view, 37–38
 mid-esophageal long-axis view, 38
 mid-esophageal right ventricular
 inflow-outflow view, 38
 mid-esophageal two-chamber
 view, 38
 transgastric mid-papillary short-
 axis view, 36
 aortic disease on, 51–52
 complications and
 contraindications, 36
 coronary ischemia assessment, 41,
 42
 pericardial disease on, 50
 cardiac tamponade, 51
 pericardial effusion, 50–51
 pressures and flow assessment, 41
 aortic valve evaluation, 41–44, 45,
 46
 mitral valve evaluation, 44–48
 tricuspid valve evaluation, 48–50
 technical concepts, 35–36
 ventricular evaluation
 left ventricular size and function,
 39, 40
 right ventricular size and
 function, 39–40, 41
 transfusion decisions
 clinical guidelines for RBC
 thresholds, 139
 hemoglobin and hematocrit
 monitoring, 143

transgastric mid-papillary short-axis view, TEE, 36	Cardio Q probe, 112–113, 115	non-cardiac output studies, 8
transpulmonary thermodilution (TPTD), 102	fluid responsiveness assessment, 84, 89	ventricles
cardiac output measurement, 1–2	carotid velocity time integrals, 88–89	TEE evaluation, 39–40, 41
EVLW measurement	FAST exam, 95	TTE evaluation, 63–64
in clinical practice, 119–120	inferior vena cava diameter evaluation, 84–86	VerifyNow system, 130, 131
principles of, 118–119	left ventricular outflow tract/aortic valve velocity time integral evaluation, 86–88	vigilance, 173
transthoracic echocardiography (TTE), 55	noninvasive CO measurement, 101, 104	Vigileo. <i>See</i> FloTrac
views and possible assessments, 55	noninvasive ICP and CBF monitoring, 12–13	viscoelastic coagulation tests, 125–126
apical four- and five-chamber views, 56, 58–61, 62	urinary bladder, FAST exam, 94	Quanta Hemostasis Analyzer, 129
parasternal long-axis view, 55–57, 58		ROTEM®, 126–128, 129
parasternal short-axis view, 56, 57–58		Sonoclot, 128–129
subcostal long- and short-axis views, 56, 60–62	validation statistics, 1	TEG®, 126–128, 129
traumatic brain injury (TBI), 11, 13–14, 26	cardiac output monitoring	visual assessment, blood loss, 139–140, 145
trend analysis, 2–3, 4–5	background, 2–3	volumetric monitoring. <i>See</i> dynamic fluid responsiveness monitors
tricuspid valve, TEE evaluation, 48–50	Bland–Altman analysis, 2–4, 6–8	VolumeView/EV 1000®, 119
Triton L&D, 141	measurement of output, 1–2	VTI _{AV} . <i>See</i> aortic valve velocity time integral
Triton OR System, 143–144	protocol design and data collection, 2	VTI _{LVOT} . <i>See</i> left ventricular outflow tract velocity time integral
TTE. <i>See</i> transthoracic echocardiography	report of validation study data, 6–8	
ultrasound. <i>See also</i> specific types	time plots and regression analysis, 5–6	wearables. <i>See</i> consumer wearables
	trend analysis, 2–3, 4–5	wireless monitoring technologies, 164–165
		blood pressure monitoring, 166
		cardiac telemetry, 165–166
		pulse oximetry, 166–167